Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells

Atherosclerosis

Volumn 254, Issue , 2016, Pages 59-66

  Zychowski, Katherine E ^a   Sanchez, Bethany ^a   Pedrosa, Rodrigo P ^b,d   Lorenzi Filho, Geraldo ^b   Drager, Luciano F ^b   Polotsky, Vsevolod Y ^c   Campen, Matthew J ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Hospital Metropolitano Sul Dom Hélder Câmara   (Brazil)

Author keywords

Bioassay; Hypoxia; Inflammation; Obstructive sleep apnea; Serum

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MESSENGER RNA; OXYGEN; PADGEM PROTEIN; RANTES; VASCULAR CELL ADHESION MOLECULE 1; ICAM1 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; SELP PROTEIN, HUMAN;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY VASCULAR RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLAMMATION; INTERMITTENT HYPOXIA; LEUKOCYTE ADHERENCE; MALE; MONOCYTE; OXYGEN SATURATION; POLYMERASE CHAIN REACTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SERUM CUMULATIVE INFLAMMATORY POTENTIAL ASSAY; SLEEP DISORDERED BREATHING; VASCULAR ENDOTHELIAL CELL; BLOOD; CASE CONTROL STUDY; CELL ADHESION; COHORT ANALYSIS; CORONARY BLOOD VESSEL; CYTOLOGY; ENDOTHELIUM CELL; GENETIC PROCEDURES; HYPOXIA; LEUKOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK FACTOR;

ADULT; BIOSENSING TECHNIQUES; CASE-CONTROL STUDIES; CELL ADHESION; COHORT STUDIES; CONTINUOUS POSITIVE AIRWAY PRESSURE; CORONARY VESSELS; ENDOTHELIAL CELLS; HUMANS; HYPOXIA; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; LEUKOCYTES; MALE; MIDDLE AGED; P-SELECTIN; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84988967952     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.09.017     Document Type: Article

References (58)

1. [1] Calvin, A.D., et al. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab. Syndr. Relat. Disord. 7:4 (2009), 271–277.
2. [2] Peppard, P.E., et al. Increased prevalence of sleep-disordered breathing in adults. Am. J. Epidemiol. 177:9 (2013), 1006–1014.
3. [3] Heinzer, R., et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir. Med. 3:4 (2015), 310–318.
4. [4] Schmidt, F.M., et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PloS One, 10(3), 2015, e0121971.
5. [5] Drager, L.F., et al. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J. Am. Coll. Cardiol. 62:7 (2013), 569–576.
6. [6] Sánchez-de-la-Torre, M., Campos-Rodriguez, F., Barbé, F., Obstructive sleep apnoea and cardiovascular disease. Lancet Respir. Med. 1:1 (2013), 61–72.
7. [7] Jelic, S., et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 117:17 (2008), 2270–2278.
8. [8] Lavie, L., Obstructive sleep apnoea syndrome–an oxidative stress disorder. Sleep. Med. Rev. 7:1 (2003), 35–51.
9. [9] Marin, J.M., et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:9464 (2005), 1046–1053.
10. [10] Bouloukaki, I., et al. Obstructive sleep apnea syndrome and cardiovascular disease: the influence of C-reactive protein. World J. Exp. Med. 5:2 (2015), 77–83.
11. [11] Ryan, S., Taylor, C.T., McNicholas, W.T., Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?. Thorax 64:7 (2009), 631–636.
12. [12] Nadeem, R., et al. Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med., 9(10), 2013, 1003.
13. [13] McNicholas, W.T., Obstructive sleep apnea and inflammation. Prog. Cardiovasc. Dis. 51:5 (2009), 392–399.
14. [14] Weaver, T.E., et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep, 30(6), 2007, 711.
15. [15] Munoz, A., et al. Long-term effects of CPAP on daytime functioning in patients with sleep apnoea syndrome. Eur. Respir. J. 15:4 (2000), 676–681.
16. [16] Karimi, M., et al. Sleep apnea-related risk of motor vehicle accidents is reduced by continuous positive airway pressure: Swedish Traffic Accident Registry data. Sleep 38:3 (2015), 341–349.
17. [17] Peppard, P.E., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342:19 (2000), 1378–1384.
18. [18] Yaggi, H.K., et al. Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 353:19 (2005), 2034–2041.
19. [19] Comondore, V.R., et al. The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung 187:1 (2009), 17–22.
20. [20] Barbe, F., et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am. J. Respir. Crit. Care Med. 181:7 (2010), 718–726.
21. [21] Barbe, F., et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 307:20 (2012), 2161–2168.
22. [22] Craig, S.E., et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax 67:12 (2012), 1090–1096.
23. [23] Cung, H., et al. Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients. J. Transl. Med., 13(1), 2015, 99.
24. [24] Agarwal, B., et al. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol., 166(1), 2013, 246.
25. [25] Aragon, M.J., et al. Inflammatory and vasoactive effects of serum following inhalation of varied complex mixtures. Cardiovasc Toxicol. 16 (2016), 163–171.
26. [26] Paffett, M.L., et al. Ozone inhalation impairs coronary artery dilation via intracellular oxidative stress: evidence for serum-borne factors as drivers of systemic toxicity. Toxicol. Sci. 146:2 (2015), 244–253.
27. [27] Drager, L.F., et al. Obstructive sleep apnea, masked hypertension, and arterial stiffness in men. Am. J. Hypertens. 23:3 (2010), 249–254.
28. [28] Drager, L.F., et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. Hypertension 57:3 (2011), 549–555.
29. −ΔΔCT method. methods 25:4 (2001), 402–408.
30. [30] Molnar, M.Z., et al. Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans. Thorax 70:9 (2015), 888–895.
31. [31] Feres, M.C., et al. An assessment of oxidized LDL in the lipid profiles of patients with obstructive sleep apnea and its association with both hypertension and dyslipidemia, and the impact of treatment with CPAP. Atherosclerosis 241:2 (2015), 342–349.
32. [32] Xu, H., et al. Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: a meta-analysis of randomized controlled trials. Atherosclerosis 234:2 (2014), 446–453.
33. [33] Chirinos, J.A., et al. CPAP, weight loss, or both for obstructive sleep apnea. N. Engl. J. Med. 370:24 (2014), 2265–2275.
34. [34] Stradling, J.R., et al. Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA. Thorax 70:2 (2015), 181–182.
35. [35] Ohga, E., et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J. Appl. Physiol. 87:1 (1999), 10–14.
36. [36] Ursavas, A., et al. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 74:5 (2007), 525–532.
37. [37] El-Solh, A.A., et al. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 121:5 (2002), 1541–1547.
38. [38] Ohga, E., et al. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J. Appl. Physiol. (1985) 94:1 (2003), 179–184.
39. [39] Lamberts, M., et al. Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. J. Intern Med. 276:6 (2014), 659–666.
40. [40] Metz, T.O., et al. Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset. J. Proteome Res. 7:2 (2008), 698–707.
41. [41] Wilson, P.W., et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern Med. 165:21 (2005), 2473–2478.
42. [42] Sever, P.S., et al. Evaluation of c-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian cardiac outcomes trial lipid-lowering arm. J. Am. Coll. Cardiol. 62:8 (2013), 717–729.
43. [43] Smoliga, J.M., Colombo, E.S., Campen, M.J., A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging (Albany NY) 5:7 (2013), 495–506.
44. [44] Channell, M.M., et al. Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: evidence from a novel translational in vitro model. Toxicol. Sci., 2012 p. kfs084.
45. [45] Jurado-Gamez, B., et al. Serum proteomic changes in adults with obstructive sleep apnoea. J. sleep Res. 21:2 (2012), 139–146.
46. [46] Kim, J., et al. Increase in serum haptoglobin and apolipoprotein M in patients with obstructive sleep apnoea. J. sleep Res. 18:3 (2009), 313–320.
47. [47] Xu, J.-X., et al. Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea. Sleep Breath., 2015, 1–7.
48. [48] Xu, Y., et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 285:30 (2010), 23233–23240.
49. [49] Kheirandish-Gozal, L., et al. Plasma-derived exosomes alter endothelial tight junction in obese children with obstructive sleep apnea: effect of adenotonsillectomy (t&a). Am. J. Respir. Crit. Care Med., 191, 2015, A2596.
50. [50] Ryan, S., Taylor, C.T., McNicholas, W.T., Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:17 (2005), 2660–2667.
51. [51] Polotsky, V.Y., et al. Intermittent and sustained hypoxia induce a similar gene expression profile in human aortic endothelial cells. Physiol. Genom. 41:3 (2010), 306–314.
52. [52] Elices, M.J., et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:4 (1990), 577–584.
53. [53] Middleton, J., et al. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100:12 (2002), 3853–3860.
54. [54] Dyugovskaya, L., Lavie, P., Lavie, L., Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 165:7 (2002), 934–939.
55. [55] Briançon-Marjollet, A., et al. Altered in vitro endothelial repair and monocyte migration in obstructive sleep apnea: implication of VEGF and CRP. Sleep, 37(11), 2014, 1825.
56. [56] Carreras, A., et al. Obstructive apneas induce early activation of mesenchymal stem cells and enhancement of endothelial wound healing. Respir. Res., 11(1), 2010, 91.
57. [57] Drager, L.F., Polotsky, V.Y., Lorenzi-Filho, G., Obstructive sleep apnea: an emerging risk factor for atherosclerosis. CHEST J. 140:2 (2011), 534–542.
58. [58] Drager, L.F., et al. Early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 172:5 (2005), 613–618.